Fly News Breaks for May 14, 2019
May 14, 2019 | 09:00 EDT
Baird analyst Madhu Kumar initiated Pieris Pharmaceuticals with an Outperform rating and $5 price target, saying he believe's Pieris' anticalin platform has the potential to disrupt biologic therapies in the respiratory and oncology spaces. The analyst called out the company's Phase 1 single ascending dose results for anti-interleukin-4 receptor a Ac PRS060 as potentially validating the drug's utility in asthma and serve as a positive catalyst for shares.
News For PIRS From the Last 2 Days
There are no results for your query PIRS